|
|
|
|
News
|
|
Big deals reshape Bay Area biotech industry
|
From Mercury News, Mar 14, 2009
By Steve Johnson
A wave of multibillion-dollar deals this week signals the acceleration of a deal-making frenzy that will likely reshape the life-sciences industry.
In the two latest, South San Francisco-based Genentech on Thursday finally agreed to a $46.8 billion deal with Roche, while Foster City-based Gilead Sciences moved the same day to snap up Palo Alto-based CV Therapeutics for $1.4 billion. Earlier this week, pharmaceutical giant Merck
...
|
|
|
|
Firms Prepare for a Fight Over Generic Drugs
|
From Wall Street Journal, Mar 12, 2009
By Alicia Mundy
Biotechnology companies are gearing up for battle on Capitol Hill after Rep. Henry Waxman, the powerful California Democrat, introduced a bill that would clear a regulatory path for generic drug makers to produce copies of biologic medicines.
Companies such as Amgen Inc. and Genentech Inc. have fought off such efforts in the past. Biologics are generally proteins manufactured in living cells, and they are far more complex
...
|
|
|
|
What's In Store For Biotechs
|
|
From Wall Street Journal, Feb 13, 2009
Jonathan Matsey
As the BIO CEO & Investor conference began to wrap up Tuesday afternoon, it was hard not to notice the glum mood among attendees, especially in the rarefied air of the Waldorf=Astoria hotel. The halls were filled with biotechnology executives and investors sounding off about the 381.99-point drop in the Dow Jones Industrial Average, while they clutched more modest-looking conference bags filled with less swag than in years pas
...
|
|
|
|
|
|
